Few neoplastic diseases have undergone a transformation in a relatively short period like
chronic myeloid leukemia (CML) has in the last few years. In 1960, CML was the first cancer …

The ubiquitin-proteasome pathway (UPP) is involved in regulating several biological
functions, including cell cycle control, apoptosis, DNA damage response, and apoptosis. It is …

Chronic myeloid leukemia (CML) is caused by the constitutively activated tyrosine kinase
breakpoint cluster (BCR)-ABL. Current frontline therapy for CML is imatinib, an inhibitor of …

To better understand the origin of leukemic stem cells, we tested the hypothesis that all
leukemia oncogenes could transform committed myeloid progenitor cells lacking the …

Imatinib is a molecularly targeted therapy that inhibits the oncogenic fusion protein BCR-
ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia …

Chronic Myeloid Leukaemia (CML) is a clonal, myeloproliferative disease that develops
when a single, pluripotential, haemopoetic stem cell acquires the Philadelphia chromosome …

Recent antitumor drug research has seen the development of a large variety of tyrosine
kinase inhibitors (TKIs) with increasing specificity and selectivity. These are highly promising …

Overexpression of P-glycoprotein, encoded by the MDR1 gene, confers multidrug resistance
(MDR) on cancer cells and is a frequent impediment to successful chemotherapy. Recent …

Imatinib (Gleevec) is currently the frontline therapy for chronic myeloid leukemia (CML), a
disease characterized by the presence of a constitutively activated chimeric tyrosine kinase …

Acute myeloid leukemia (AML) and Chronic myelogenous leukemia (CML) are common
leukemia in adults. 20 (S)-GRh2 is an important bioactive substance that is present in Panax …